HAEMONETICS CORP/MASS

Haemonetics (HAE) Shifts Upward: Strong Momentum, Solid Valuation, and a 200‑Day SMA Support Boost

Haemonetics (HAE) shows steady growth amid volatile peers, offering a solid entry near $116 with strong 200‑day SMA support and a clear upside potential.

HAEMONETICS CORP/MASS
United States
Health Care
Health Care Equipment & Services
AI generated

Vanessa Liu

23/10/2026, 11:24

3 minutes to read

Haemonetics Corp (MASS): Plasma Platform Shift & New Alentis Partnership Drive 2027 Growth Outlook

Haemonetics (MASS) drops 0.93% as it plans NexSys plasma transition and partners with Alentis on rare kidney/liver therapies, boosting its specialty medicine pipeline.

HAEMONETICS CORP/MASS
United States
Health Care
Health Care Equipment & Services
AI generated

Elliot Mercer

22/10/2026, 18:20

2 minutes to read

Haemonetics Shares Dip Slightly, Still Above 200‑Day MA in Stable Health‑Tech Market

Haemonetics (HAE) trades above its 200‑day average at $118.21, showing modest decline amid mixed market sentiment. Discover why the blood‑processing leader remains a stable healthcare stock.

HAEMONETICS CORP/MASS
United States
Health Care
Health Care Equipment & Services
AI generated

Jake Connors

21/10/2026, 11:54

3 minutes to read